High--throughput screening of FDA--approved drugs identifies novel immunomodulatory agents for immune-mediated skin diseases

被引:0
|
作者
Ghorbanalipoor, S. [1 ]
Matsumoto, K. [1 ]
Heimberg, L. [1 ]
Krause, M. [1 ]
Veldkamp, W. [2 ]
Magens, M. [1 ]
Zanken, J. [1 ]
Vidarsson, G. [3 ,4 ]
Visser, R. [3 ,4 ]
Kuenzel, S. [5 ]
Recke, A. [6 ,7 ]
Samavedam, U. [1 ]
Gupta, Y. [1 ]
Zillikens, D. [6 ,7 ]
Bieber, K. [1 ]
Ludwig, R. J. [1 ]
机构
[1] Univ Lubeck, D-23562 Lubeck, Germany
[2] Radboudumc, Univ Clin, Nijmegen, Netherlands
[3] Sanquin Res, Amsterdam, Netherlands
[4] Landsteiner Lab, Amsterdam, Netherlands
[5] Max Planck Inst Evolutionary Biol, Plon, Germany
[6] Univ Lubeck, Dept Dermatol, D-23562 Lubeck, Germany
[7] Ctr Res Inflammat Skin, D-23562 Lubeck, Germany
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P094
引用
收藏
页码:E46 / E46
页数:1
相关论文
共 50 条
  • [11] High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases
    Aldewachi, Hasan
    Al-Zidan, Radhwan N.
    Conner, Matthew T.
    Salman, Mootaz M.
    BIOENGINEERING-BASEL, 2021, 8 (02): : 1 - 20
  • [12] Screening a library of FDA-approved drugs identifies agents that induce lytic viral infection in EBV-associated tumors.
    Chen, J.
    Chong, C.
    Hsieh, W.
    Fu, D.
    Lemas, V.
    Liu, J. O.
    Ambinder, R. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 79S - 79S
  • [13] Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study
    Opdam, Merel A. A.
    Vriezekolk, Johanna E.
    Broen, J.
    den Broeder, Alfons A.
    Verhoef, Lise M.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 7 (01)
  • [14] High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2
    Wan, Weiwei
    Zhu, Shenglin
    Li, Shufen
    Shang, Weijuan
    Zhang, Ruxue
    Li, Hao
    Liu, Wei
    Xiao, Gengfu
    Peng, Ke
    Zhang, Leike
    ACS INFECTIOUS DISEASES, 2021, 7 (06): : 1409 - 1422
  • [15] Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study
    Srivastava, Varshita
    Naik, Biswajit
    Godara, Priya
    Das, Dorothy
    Mattaparthi, Venkata Satish Kumar
    Prusty, Dhaneswar
    MOLECULAR DIVERSITY, 2024, 28 (03) : 1093 - 1107
  • [16] High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects
    Sahdeo, Sunil
    Tomilov, Alexey
    Komachi, Kelly
    Iwahashi, Christine
    Datta, Sandipan
    Hughes, Owen
    Hagerman, Paul
    Cortopassi, Gino
    MITOCHONDRION, 2014, 17 : 116 - 125
  • [17] High-content screening assay for compounds that enhance or inhibit leukocyte superoxide production to identify drugs for treating immune-mediated diseases
    Wu, Szu-Yu Szu
    Shieh, Chi-Chang K.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [18] Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
    Gomez-Garcia, Francisco
    Jesus Gomez-Arias, Pedro
    Hernandez, Jorge
    Maria Montilla, Ana
    Gay-Mimbrera, Jesus
    Aguilar-Luque, Macarena
    Viguera-Guerra, Isabel
    Velez Garcia-Nieto, Antonio
    Isla-Tejera, Beatriz
    Ruano, Juan
    BMJ OPEN, 2019, 9 (05):
  • [19] Synthetic Lethality Screening Identifies FDA-Approved Drugs That Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin
    Mariniello, Marta
    Petruzzelli, Raffaella
    Wanderlingh, Luca G.
    La Montagna, Raffaele
    Carissimo, Annamaria
    Pane, Francesca
    Amoresano, Angela
    Ilyechova, Ekaterina Y.
    Galagudza, Michael M.
    Catalano, Federico
    Crispino, Roberta
    Puchkova, Ludmila V.
    Medina, Diego L.
    Polishchuk, Roman S.
    CANCERS, 2020, 12 (03)
  • [20] Using claims data to identify the exact indication of use for biological drugs approved for immune-mediated inflammatory diseases: The VALORE project experience
    Spini, Andrea
    Ientile, Valentina
    Fontana, Andrea
    Ingrasciotta, Ylenia
    Tanaglia, Matilde
    Lopes, Sara
    Belleudi, Valeria
    Trifiro, Gianluca
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 277 - 278